New technologies and new business models are transforming life science companies. A new book from Accenture maps out the fresh approaches being taken across healthcare.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh